BeiGene Rebrands as BeOne Medicines, Switches Nasdaq Ticker to "ONC" Starting January 2, 2025

BeiGene Ltd. (currently trading under NASDAQ: BGNE) is making a strategic pivot that underscores its focused mission in the oncology sector. The company has announced it will rebrand to BeOne Medicines Ltd. and transition its Nasdaq ticker symbol to “ONC” effective January 2, 2025—a move designed to crystallize the organization’s core identity around innovative cancer treatment solutions.

What’s Behind the Name and Ticker Change?

The transformation reflects BeiGene’s decade-and-a-half journey in the pharmaceutical space and its evolving strategy as it enters its 15th operational year. John V. Oyler, Co-Founder, Chairman and CEO, framed the shift as emblematic of the company’s persistent drive to lead in oncology therapeutics. “This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere,” Oyler stated.

For investors tracking the company’s beiGene share price on Nasdaq, the ticker transition won’t affect underlying ownership or the CUSIP number—shareholders require no action to execute the change. Trading mechanics on The Stock Exchange of Hong Kong (HKEX: 06160) and Shanghai Stock Exchange’s STAR Market (SSE: 688235) will remain unaffected.

Upcoming Investor Engagement: J.P. Morgan Healthcare Conference

BeOne Medicines will showcase its pipeline progress at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, with a presentation scheduled for 1:30 pm PT. This high-profile healthcare investment forum provides a platform for the company to detail its hematology advancements and oncology pipeline momentum to institutional investors and industry stakeholders. A live webcast will be accessible via the company’s Investor Relations portal, with replays available for 30 days post-event.

Company Overview and Strategic Direction

Now operating as BeOne Medicines, the organization maintains its commitment to discovering and developing more affordable, accessible oncology treatments globally. With nearly 11,000 employees spanning five continents, the company operates both internal R&D capabilities and strategic collaborations to expedite therapeutic development across its diverse pipeline. The rebrand underscores a singular focus: transforming cancer care accessibility for patients worldwide while advancing novel hematology and solid tumor programs.

The transition represents more than a cosmetic change—it signals BeOne Medicines’ intent to sharpen its market positioning as a specialized oncology-focused enterprise navigating an increasingly competitive pharmaceutical landscape.